Now showing items 1-1 of 1

    Issue DateTitleAuthor(s)
    2 September 2020Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT  Earl, H; Hiller, L; Vallier, A-L; et al.